Literature DB >> 29714003

Healthcare Databases for Drug Safety Research: Data Validity Assessment Remains Crucial.

Nigel S B Rawson1,2,3, Carl D'Arcy4.   

Abstract

Administrative healthcare utilization databases are frequently used either individually or as a component of aggregated data for evaluating drug safety issues without taking into account their known deficiencies. All too often insufficient evidence is provided about their validity for the purposes for which they are used. The assessment of data validity is a key constituent that should be included in drug safety research studies and should take a broad multifaceted approach that encompasses both diagnostic and drug exposure data. Drug safety researchers need to continue advancing their knowledge of the data resources they use and to ensure that they and the users of their research understand the limitations of the data that are the foundation on which their research is built. Fundamental issues regarding data validity should be addressed in each use of administrative data for drug safety research.

Entities:  

Mesh:

Year:  2018        PMID: 29714003     DOI: 10.1007/s40264-018-0673-z

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  43 in total

Review 1.  Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions.

Authors:  Andrea C Tricco; Ba' Pham; Nigel S B Rawson
Journal:  J Clin Epidemiol       Date:  2007-08-03       Impact factor: 6.437

2.  The development of a comprehensive psychiatric service utilization research data file.

Authors:  C D'Arcy; M V Ham; S Goldie
Journal:  Can J Public Health       Date:  1976 May-Jun

3.  Reliability of the recording of hysterectomy in the Saskatchewan health care system.

Authors:  L Edouard; N S Rawson
Journal:  Br J Obstet Gynaecol       Date:  1996-09

4.  Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles.

Authors:  N S Rawson; E Malcolm; C D'Arcy
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-05       Impact factor: 4.328

Review 5.  Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  Drug Saf       Date:  2015-07       Impact factor: 5.606

6.  Concordance on the recording of cancer in the Saskatchewan Cancer Agency Registry, hospital charts and death registrations.

Authors:  N S Rawson; D L Robson
Journal:  Can J Public Health       Date:  2000 Sep-Oct

7.  Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983.

Authors:  H A Guess; R West; L M Strand; D Helston; E G Lydick; U Bergman; K Wolski
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

8.  An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients.

Authors:  Carol E Koro; Qinggong Fu; Monika Stender
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-10       Impact factor: 2.890

9.  Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles.

Authors:  N S Rawson; E Malcolm
Journal:  Stat Med       Date:  1995-12-30       Impact factor: 2.373

10.  Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Authors:  David N Juurlink; Tara Gomes; Lorraine L Lipscombe; Peter C Austin; Janet E Hux; Muhammad M Mamdani
Journal:  BMJ       Date:  2009-08-18
View more
  2 in total

Review 1.  Breastfeeding, pregnancy, medicines, neurodevelopment, and population databases: the information desert.

Authors:  Sue Jordan; Rebecca Bromley; Christine Damase-Michel; Joanne Given; Sophia Komninou; Maria Loane; Naomi Marfell; Helen Dolk
Journal:  Int Breastfeed J       Date:  2022-08-02       Impact factor: 3.790

Review 2.  Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Gian Paolo Fadini; Giulio Marchesini; Fabrizio De Ponti
Journal:  Diabetes Obes Metab       Date:  2018-08-14       Impact factor: 6.577

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.